Cargando…

Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase

The pathology of Alzheimer’s disease (AD) is characterized by dystrophic neurites (DNs) surrounding extracellular Aβ-plaques, microgliosis, astrogliosis, intraneuronal tau hyperphosphorylation and aggregation. We have previously shown that inhibition of the spleen tyrosine kinase (Syk) lowers Aβ pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweig, Jonas Elias, Yao, Hailan, Beaulieu-Abdelahad, David, Ait-Ghezala, Ghania, Mouzon, Benoit, Crawford, Fiona, Mullan, Michael, Paris, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588676/
https://www.ncbi.nlm.nih.gov/pubmed/28877763
http://dx.doi.org/10.1186/s40478-017-0472-2
_version_ 1783262220531007488
author Schweig, Jonas Elias
Yao, Hailan
Beaulieu-Abdelahad, David
Ait-Ghezala, Ghania
Mouzon, Benoit
Crawford, Fiona
Mullan, Michael
Paris, Daniel
author_facet Schweig, Jonas Elias
Yao, Hailan
Beaulieu-Abdelahad, David
Ait-Ghezala, Ghania
Mouzon, Benoit
Crawford, Fiona
Mullan, Michael
Paris, Daniel
author_sort Schweig, Jonas Elias
collection PubMed
description The pathology of Alzheimer’s disease (AD) is characterized by dystrophic neurites (DNs) surrounding extracellular Aβ-plaques, microgliosis, astrogliosis, intraneuronal tau hyperphosphorylation and aggregation. We have previously shown that inhibition of the spleen tyrosine kinase (Syk) lowers Aβ production and tau hyperphosphorylation in vitro and in vivo. Here, we demonstrate that Aβ-overexpressing Tg PS1/APPsw, Tg APPsw mice, and tau overexpressing Tg Tau P301S mice exhibit a pathological activation of Syk compared to wild-type littermates. Syk activation is occurring in a subset of microglia and is age-dependently increased in Aβ-plaque-associated dystrophic neurites of Tg PS1/APPsw and Tg APPsw mice. In Tg Tau P301S mice, a pure model of tauopathy, activated Syk occurs in neurons that show an accumulation of misfolded and hyperphosphorylated tau in the cortex and hippocampus. Interestingly, the tau pathology is exacerbated in neurons that display high levels of Syk activation supporting a role of Syk in the formation of tau pathological species in vivo. Importantly, human AD brain sections show both pathological Syk activation in DNs around Aβ deposits and in neurons immunopositive for pathological tau species recapitulating the data obtained in transgenic mouse models of AD. Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species. Given that we have previously shown that Syk activation also promotes Aβ formation and tau hyperphosphorylation, our data suggest that AD pathological lesions may be self-propagating via a Syk dependent mechanism highlighting Syk as an attractive therapeutic target for the treatment of AD.
format Online
Article
Text
id pubmed-5588676
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55886762017-09-14 Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase Schweig, Jonas Elias Yao, Hailan Beaulieu-Abdelahad, David Ait-Ghezala, Ghania Mouzon, Benoit Crawford, Fiona Mullan, Michael Paris, Daniel Acta Neuropathol Commun Research The pathology of Alzheimer’s disease (AD) is characterized by dystrophic neurites (DNs) surrounding extracellular Aβ-plaques, microgliosis, astrogliosis, intraneuronal tau hyperphosphorylation and aggregation. We have previously shown that inhibition of the spleen tyrosine kinase (Syk) lowers Aβ production and tau hyperphosphorylation in vitro and in vivo. Here, we demonstrate that Aβ-overexpressing Tg PS1/APPsw, Tg APPsw mice, and tau overexpressing Tg Tau P301S mice exhibit a pathological activation of Syk compared to wild-type littermates. Syk activation is occurring in a subset of microglia and is age-dependently increased in Aβ-plaque-associated dystrophic neurites of Tg PS1/APPsw and Tg APPsw mice. In Tg Tau P301S mice, a pure model of tauopathy, activated Syk occurs in neurons that show an accumulation of misfolded and hyperphosphorylated tau in the cortex and hippocampus. Interestingly, the tau pathology is exacerbated in neurons that display high levels of Syk activation supporting a role of Syk in the formation of tau pathological species in vivo. Importantly, human AD brain sections show both pathological Syk activation in DNs around Aβ deposits and in neurons immunopositive for pathological tau species recapitulating the data obtained in transgenic mouse models of AD. Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species. Given that we have previously shown that Syk activation also promotes Aβ formation and tau hyperphosphorylation, our data suggest that AD pathological lesions may be self-propagating via a Syk dependent mechanism highlighting Syk as an attractive therapeutic target for the treatment of AD. BioMed Central 2017-09-06 /pmc/articles/PMC5588676/ /pubmed/28877763 http://dx.doi.org/10.1186/s40478-017-0472-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schweig, Jonas Elias
Yao, Hailan
Beaulieu-Abdelahad, David
Ait-Ghezala, Ghania
Mouzon, Benoit
Crawford, Fiona
Mullan, Michael
Paris, Daniel
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title_full Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title_fullStr Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title_full_unstemmed Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title_short Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
title_sort alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588676/
https://www.ncbi.nlm.nih.gov/pubmed/28877763
http://dx.doi.org/10.1186/s40478-017-0472-2
work_keys_str_mv AT schweigjonaselias alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT yaohailan alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT beaulieuabdelahaddavid alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT aitghezalaghania alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT mouzonbenoit alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT crawfordfiona alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT mullanmichael alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase
AT parisdaniel alzheimersdiseasepathologicallesionsactivatethespleentyrosinekinase